Global Healthcare Opportunities said Monday that it acquired Genesis Research, a Hoboken-based provider of tech-enabled real-world evidence and health economics and outcomes research services.
Genesis has an established footprint in the U.S. and the U.K., with more than 120 employees. Founded in 2009, it is a pioneer in RWE and HEOR services via tech-enabled data and science-first solutions, servicing innovators across the life sciences industry. It optimizes drug development and evidences the clinical and commercial value of products via expert analysis, synthesis, communication and utilization of integrated real-world data.
With estimated double-digit growth year-over-year, and regulatory demands accelerating the volume and accessibility of RWD, Genesis Research’s purpose-built technology platforms integrate human and artificial intelligence to increase efficiency and improve performance to meet expanding market needs.
Genesis’ best-of-breed technology solutions are built into its workflow and targeted to accelerate and optimize delivery of desired scientific outcomes: EVID AI, the world’s largest AI-curated database of published literature; data-agnostic visualization platforms, such as fit-for-purpose dashboards; The company’s Landscape Evidence Overview, or LEO, platform; and evidence for value and access technology.
With a broad base of blue-chip pharmaceutical manufacturers and emerging biotechnology companies, Genesis is an established leader and one of the largest operators within a highly fragmented sector.
GHO will provide further capital and sector expertise as well as leverage its European network to build on Genesis’ unique market position and drive expansion into adjacent service offerings to create a scaled global leader in tech-enabled RWE and HEOR services.
Genesis has announced that David Miller will be appointed as the new chairman of the board and will formally assume the role in 2022.
Ropes & Gray acted as legal adviser to GHO; CIL as commercial adviser; Alvarez and Marsal as financial adviser; Deloitte LLP as tax adviser; and CRS as insurance adviser.
In this transaction, Berg Hill Greenleaf Ruscitti acted as legal adviser to Genesis Research; Piper Sandler Cos. as exclusive corporate finance adviser and RSM Global as tax adviser.
